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Abstract
The activation of phase-specific cyclin-dependent kinases (Cdks) is associated with ordered cell cycle transitions. Among the
mammalian Cdks, only Cdk1 is essential for somatic cell proliferation. Cdk1 can apparently substitute for Cdk2, Cdk4, and
Cdk6, which are individually dispensable in mice. It is unclear if all functions of non-essential Cdks are fully redundant with
Cdk1. Using a genetic approach, we show that Cdk2, the S-phase Cdk, uniquely controls the G2/M checkpoint that prevents
cells with damaged DNA from initiating mitosis. CDK2-nullizygous human cells exposed to ionizing radiation failed to
exclude Cdk1 from the nucleus and exhibited a marked defect in G2/M arrest that was unmasked by the disruption of P53.
The DNA replication licensing protein Cdc6, which is normally stabilized by Cdk2, was physically associated with the
checkpoint regulator ATR and was required for efficient ATR-Chk1-Cdc25A signaling. These findings demonstrate that Cdk2
maintains a balance of S-phase regulatory proteins and thereby coordinates subsequent p53-independent G2/M checkpoint
activation.
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Introduction
Cdks associate with cyclins to form heterodimers that are
sequentially activated during the cell cycle. Metazoan cells have
multiple Cdks and cyclins that are temporally regulated [1,2]. In
normal cell cycles, Cdk4 and Cdk6 pair with D-type cyclins during
G1, Cdk2 pairs with E- and A-type cyclins during S and G2, and
Cdk1 pairs with A- and B-type cyclins during G2 and M. The
importance of Cdks in cell cycle transitions was suggested by
studies in which expression of dominant negative mutants or
introduction of inhibitory antibodies or small molecule inhibitors
caused phase-specific cell cycle arrest [3]. However recent genetic
studies have called into question the requirement for multiple Cdks
[3–5]. RNAi-mediated depletion of Cdks in human cells [6] and
gene knockouts in mice [7–10] showed that Cdk2, Cdk4 and Cdk6
are dispensable for cell cycle progression. Cdk1 can bind D-, E-,
and A-type cyclins and functionally substitute for the non-essential
Cdks [11]. While it is clear that Cdk1 alone can drive unperturbed
cell cycle progression, it remains unclear whether the non-essential
Cdks have non-redundant functions in cell cycle responses to
stress.
Cdks are targeted by checkpoints that halt the cell cycle in
response to DNA damage. Cdk2 is primarily considered a
downstream target of the S-phase checkpoint [12,13]. However
Cdk2 can also signal upstream via the phosphorylation of ATRIP,
a binding partner of the ATR kinase [14]. Despite this data
suggesting a role for Cdk2 in the regulation of checkpoint
signaling, conflicting genetic evidence challenges the functional
requirement for Cdk2 in DNA damage responses. Both the G1/S
and G2/M checkpoints appear to remain fully functional in
CDK2
2/2 mouse embryonic fibroblasts (MEFs) [15,16]. As Cdk2
and Cdk1 are functionally redundant in supporting DNA
replication, it would seem plausible that Cdk1 could similarly
substitute for Cdk2 in checkpoint pathways. Such redundancy
would account for the lack of apparent checkpoint defects in the
mouse CDK2-knockout.
Here we show that Cdk2 uniquely activates the G2/M
checkpoint and that this function is masked by the presence of
p53, which functions independently to arrest cells in G2 after DNA
damage. Unlike the functions of Cdk2 during unperturbed S-
phase, the role of Cdk2 in the G2/M checkpoint is non-redundant
and cannot be performed by Cdk1.
Results
Stabilization of Cdc25A in Cdk2-deficient cells
Does Cdk2 contribute to human checkpoints? We first tested
whether Cdk2 is required for the regulation of Cdc25A, a common
target of checkpoint kinases and a critical mediator of cell cycle
transitions. Depletion of Cdk2 with siRNA resulted in increased
Cdc25A protein levels in human colorectal cancer cells (Figure 1A).
To unambiguously evaluate the role of Cdk2 in checkpoint
responses, we disrupted both CDK2 alleles in the human colorectal
cancer cell line HCT116 (Figure 1B). HCT116 cells have intact
DNA damage-responsive checkpoints [17–19] and detailed
analysis of these cells has revealed that p53 is required for
maintaining stable arrest at G1/S and at G2/M after ionizing
radiation (IR) [17]. To compare the contributions of p53 and
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2/2
and CDK2
2/2 cells, respectively, and together to generate double
knockout cells (CDK2
2/2 P53
2/2). Two double knockout clones
were obtained in independent experiments. As expected, homozy-
gous disruption of P53 and CDK2 led to loss of protein expression
in a genotype-specific manner (Figure 1C). Consistent with the
established role of Cdk2 in promoting the G1-S transition,
asynchronous CDK2
2/2 cells exhibited an elevated G1 fraction
with fewer cells in S-phase (Figure 1E). Following IR treatment,
60% of CDK2
2/2 cells arrested at G1/S (Figure 1E), consistent
with previous observations of an intact G1/S checkpoint in
CDK2
2/2 MEFs [15,16]. P53 disruption caused a characteristic
loss of the G1/S checkpoint, irrespective of CDK2 genotype
(Figure 1E). Stabilization of p53 and the induction of its down-




2/2 backgrounds, Cdk2 deficiency resulted
in increased Cdc25A (Figure 1C). Cdc25A protein levels are
known to be tightly controlled by phosphorylation, in both stressed
and unstressed cells [20,21]. To determine if increased Cdc25A
protein following loss of Cdk2 was due to changes in stability, we
assessed Cdc25A turnover by treating HCT116 and CDK2
2/2
cells with the protein synthesis inhibitor cycloheximide. While
Cdc25A was degraded by 90 min in CDK2
2/2 cells, the rate of
Figure 1. Altered cell cycle regulation and increased Cdc25A protein in Cdk2-deficient human cancer cells. (A) Human colorectal cancer
cells HCT116 and SW480 transfected with control (Con) or CDK2 (CDK2) siRNA. Levels of Cdc25A and Cdk2 were analyzed by immunoblot. a-tubulin
was assessed as a loading control. (B) CDK2 targeting strategy. Exons 2-5 at the CDK2 locus were replaced upon integration of the knockout vector. (C)
Levels of Cdc25A, Cdk2 and p53 were determined by immunoblot in parental cells and single and double knockout cells. (D) Isogenic HCT116 cells
were harvested at the indicated times after cycloheximide treatment. Cdc25A protein levels were analyzed by immunoblot, quantitated, normalized
to a-tubulin and represented as a percentage relative to untreated control cells. (E) Isogenic HCT116 cells were fixed and stained with Hoechst 33258




Metazoan cells contain multiple Cdks that regulate cell
cycle progression. Recent studies have shown that mouse
cells can grow normally with just Cdk1. The roles of the
non-essential Cdks remain a fundamental question. In this
study, we describe the generation and detailed character-
ization of CDK2-knockout human somatic cells. Our study
demonstrates that Cdk2 is required for robust DNA
damage checkpoint signaling. Loss of Cdk2 caused a
marked deficiency in the G2/M arrest—a basic response to
DNA damage—in cells that were also nullizygous for P53.
We propose that the multiple Cdks present in metazoan
cells provide a mechanism by which the cell cycle can be
efficiently halted after DNA damage. Significantly, this
study reveals a heretofore unrecognized dependence for
Cdk2 in p53-deficient cancer cells.
Cdk2 Controls G2/M Checkpoint Signaling
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contributes to normal Cdc25A protein turnover.
Cdk2 and p53 cooperatively mediate G2/M checkpoint
arrest
To assess the integrity of the G2/M checkpoint response to
DNA double strand breaks, we treated isogenic cultures with IR
and trapped the cells that subsequently entered mitosis with the
microtubule-destabilizing drug nocodazole. Cells of all genotypes
arrested normally in mitosis when treated with nocodazole alone
(Figure 2A). p53-deficient cells do not stably arrest at G2/M
following IR [17], and therefore exhibited a modest increase in
mitotic entry after 48–60 h, compared with wild type cells in
which the mitotic index remained below 4% (Figure 2A). The
extent of mitotic entry was greatly elevated in double knockout
cells (CDK2
2/2 P53
2/2; Figure 2A). Accordingly, the mitotic
marker phospho-histone H3 S10 (H3S10-P) was strongly
expressed in CDK2
2/2 P53
2/2 cells 48 h following IR/nocoda-
zole treatment (Figure 2B). Unirradiated cells entered mitosis
within 24 h of the addition of nocodazole (Figure 2A). The
temporal delay in the mitotic entry of irradiated double knockout
cells compared with unirradiated controls suggests that checkpoint
pathways were activated in the absence of Cdk2 and p53, but were
apparently insufficient to facilitate stable arrest. This G2/M
checkpoint defect was apparent over a range of IR doses (Figure
S1A) and could be detected as early as 24 h after IR/nocodazole
treatment (Figure 2 and Figure S1A). In contrast, the majority of
CDK2 knockout-P53 wild type cells (CDK2
2/2) arrested at G1/S
after IR treatment, and the remaining subpopulation (about 40%)
of these cells arrested at G2/M with 4N DNA content (Figure 1E).
A very small number of these 4N cells entered mitosis over the
course of the experiment (Figure 2 and Figure S1A). We conclude
that Cdk2 plays an important role in G2/M arrest after DNA
damage and that the requirement for Cdk2 was masked by the
function of p53 at both the G1/S and G2/M checkpoints.
Cdk2-null cells fail to sequester Cdk1 in the cytoplasm
after IR
The G2-M transition is controlled in part by Cdk1 localization. In
unperturbed cells, Cdk1 is cytoplasmic during interphase and enters
the nucleus in prophase to trigger mitosis. After DNA damage, Cdk1 is
excluded from the nucleus, thus contributing to arrest in G2 [22,23].
CDK2
2/2 MEFs have been reported to exhibit altered Cdk1
localization [15]. In these cells, deregulated Cdk1 localization has
been attributed to the redistribution of cyclin E, normally associated
with Cdk2, to Cdk1 [15]. Several studies demonstrate a similar
redistribution of the nuclear protein cyclin A to Cdk1 in the absence
of Cdk2 in both mouse and human cells [11,15,24,25], and such
complexes have been shown to promote mitotic entry [26–30].
Consistent with these previous studies, the amount of cyclin E
and cyclin A associated with Cdk1 was increased in CDK2-
knockout human cells (Figure 3A). As Cdk localization is
Figure 2. Cdk2 is required for G2/M arrest in p53-deficient cells. (A,B) Entry into mitosis was assessed by incubation of untreated or irradiated
(12 Gy) isogenic HCT116 cells in 0.2 mg/ml nocodazole. Two independent CDK2
2/2 P53
2/2 clones are shown. Cells were collected at the indicated
times. (A) Cells were fixed and stained with Hoechst 33258. Mitotic chromosome condensation was determined by fluorescence microscopy, images
were taken at 636magnification (scale bar, 10 mm). (B) Levels of histone H3S10-P were determined by immunoblot.
doi:10.1371/journal.pgen.1000863.g002
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PLoS Genetics | www.plosgenetics.org 3 February 2010 | Volume 6 | Issue 2 | e1000863Figure 3. Aberrant localization of Cdk1 in Cdk2-deficient cells after IR treatment. (A) Association between Cdk1 and cyclins E and A was
determined by immunoprecipitation/immunoblot. Non-denatured cell lysates were subjected to immunoprecipitation (IP) with anti-Cdk1 or control
(IgG) antibodies. Samples not subjected to immunoprecipitation were analyzed as whole cell lysate. Levels of Cdk1 and cyclins B1, E, and A were
determined by immunoblot. (B) Cdk1 levels in nuclear and cytoplasmic fractions were determined by immunoblot at the indicated times after
treatment with 12 Gy IR. Loading of nuclear and cytoplasmic proteins was assessed by probing levels of Orc2 and a-tubulin, respectively. (C)
Localization of Cdk1 by indirect immunofluorescence. Isogenic HCT116 cells were fixed 24 h after treatment with 12 Gy IR, stained with Cdk1
antibody (green) and counterstained with DAPI (blue). Representative fields are shown under low (206) and high (636) magnification (scale bar,
50 mm under 206magnification and 10 mm under 636magnification). (D–F) Localization of cyclins by indirect immunofluorescence. Isogenic HCT116
cells were fixed 24 h after treatment with 12 Gy IR, stained with (D) cyclin B1, (E) cyclin E or (F) cyclin A antibodies (green) and counterstained with
DAPI (blue). Representative fields are shown under 406magnification (scale bar, 10 mm).
doi:10.1371/journal.pgen.1000863.g003
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changes in Cdk1-cyclin complexes observed in CDK2
2/2 cells
might affect Cdk1 localization.
Total Cdk1 protein levels were unaffected by CDK2 genotype or
IR (Figure 3A and Figure S1C). After IR treatment, the amount of
Cdk1 in the nucleus was increased in CDK2
2/2 cells compared to
wild type cells (Figure 3B). The increase in nuclear Cdk1 was
independent of P53 genotype, and temporally preceded entry of
double knockout cells into mitosis (Figure 3B). Together, these
data suggest that aberrant nuclear Cdk1 was a cause rather than a
consequence of defective G2/M checkpoint function in CDK2
2/2
P53
2/2 cells. The failure of CDK2-knockout cells to exclude Cdk1
from the nucleus in response to IR was confirmed by
immunofluorescence. The localization of Cdk1 in untreated cells
was similar in HCT116 and all isogenic derivatives (data not
shown). By 24 h after IR, virtually all cells with wild type CDK2
had sequestered Cdk1 in the cytoplasm, while CDK2
2/2 cells
exhibited Cdk1 staining in both the nuclear and cytoplasmic
compartments (Figure 3C).
To determine which cyclin partners might contribute to the
altered Cdk1 localization in CDK2
2/2 cells, we examined the
localization of cyclin B1, cyclin A and cyclin E after IR. Cyclin B1
was cytoplasmic in all cell lines (Figure 3D), suggesting that
aberrant nuclear localization of Cdk1 was not caused by
deregulated cyclin B1 localization. In contrast, cyclins E and A
were nuclear in checkpoint-proficient P53-wild type cells
(Figure 3E and 3F). Cyclin E was barely detectable in P53
2/2
cells after IR (Figure 3E), presumably because these cells bypass
the G1/S checkpoint and progress to G2/M wherein cyclin E is
not normally expressed; cyclin A, which is normally expressed
from interphase until prometaphase, was located in the nucleus in
these cells (Figure 3F). In agreement with studies of CDK2
2/2
MEFs [15], these findings suggest that the redistribution of cyclin
E and cyclin A to Cdk1 results in its aberrant localization to the
nucleus after DNA damage.
Deregulation of Cdc25A is a cause of G2/M checkpoint
failure
In addition to localization, Cdk1 is also controlled by inhibitory
phosphorylation. The Cdc25A phosphatase promotes mitotic
entry by removing the inhibitory Y15 phosphate moiety on
Cdk1 (Cdk1Y15-P) [33]. This mode of activation is turned off
following IR, when Cdc25A is degraded in a Chk1-dependent
manner [20]. Cdk1 Y15 phosphorylation is a p53-independent
checkpoint mechanism [33].
The increased Cdc25A protein levels in untreated, Cdk2-
deficient cells (Figure 1C and 1D) prompted us to examine
whether Cdc25A was also aberrantly regulated in response to IR.
While Cdc25A was rapidly degraded after IR in wild type cells,
Cdc25A levels remained high in cells lacking Cdk2 (Figure 4A).
Next, we asked whether the failure to degrade Cdc25A after IR
affected the ability of CDK2-knockout cells to induce Cdk1Y15-P
and arrest at G2/M. As expected, p53-deficient cells normally
Figure 4. Impaired degradation of Cdc25A in Cdk2-deficient cells contributes to G2/M checkpoint defect. (A) Isogenic HCT116 cells
were harvested at the indicated times after treatment with 12 Gy IR. Cdc25A levels were determined by immunoblot. (B) Non-denatured cell lysates
were collected before and 24 h after 12 Gy IR. Cdk1 was immunoprecipitated (IP) and analyzed for phosphorylation on Y15 by immunoblot. Cdk1Y15-
P was quantitated and normalized to total Cdk1. (C) Stable knockdown of Cdc25A in CDK2
2/2 P53
2/2 cells by retrovirus-mediated delivery of empty
vector control (vector) or CDC25A shRNA (shCDC25A), assessed by immunoblot. (D) Cdc25A knockdown or control CDK2
2/2 P53
2/2 cells were treated
with 12 Gy IR and 0.2 mg/ml nocodazole. Histone H3S10-P levels were determined by immunoblot. (E) Mitotic indices of Cdc25A-knockdown and
control CDK2
2/2 P53
2/2 cells at the indicated times after treatment with 12 Gy IR and 0.2 mg/ml nocodazole. Error bars represent s.e.m. from six
knockdown clones.
doi:10.1371/journal.pgen.1000863.g004
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Cdk1Y15-P did not increase after IR in cells that were also Cdk2-
deficient. Interestingly, the phosphorylation of Cdk1 Y15 was
increased in untreated Cdk2-deficient cells compared to untreated
cells with wild type Cdk2 (Figure 4B). This increase in basal
Cdk1Y15-P could be a consequence of the redistribution of Cdk1
to alternative Cdk1-cyclin heterodimers and the consequent
expansion of the role of Cdk1 to multiple phases of the cell cycle,
in Cdk2-deficient cells (Figure 3A) [11,15,24,25]. It is unknown if
non-canonical Cdk1-cyclin heterodimers are efficient substrates
for activating phosphatases and inhibitory kinases.
To assess the relevance of increased Cdc25A protein levels to
the observed checkpoint defect, we tested whether stable depletion
of Cdc25A could restore checkpoint function. Depletion of
Cdc25A in CDK2
2/2 P53
2/2 cells using short hairpin RNAs
(Figure 4C) suppressed histone H3S10-P induction (Figure 4D)
and mitotic chromosome condensation (Figure 4E) after IR/
nocodazole treatment. Mitotic entry of unirradiated cells was not
affected by Cdc25A knockdown (Figure S1B). These results show
that elevated Cdc25A contributes significantly to the checkpoint
defect.
Cdk2 facilitates ATR-Chk1-Cdc25A pathway activation in
part by stabilizing Cdc6
Cdc25A protein stability is regulated by two pathways in
response to IR. ATM phosphorylates the checkpoint kinase Chk2
[34], which then triggers Cdc25A degradation [12]. Cdc25A is
also targeted for IR-dependent degradation by Chk1 [21], which is
activated after phosphorylation by ATR on residues S317 and
S345 [35,36]. The ATR-Chk1 signaling pathway is active at a
reduced physiological level during unperturbed cell growth, and
regulates basal Cdc25A protein turnover during S-phase [21].
IR-induced phosphorylation of Chk1 S317 and S345 was
reduced in CDK2-knockout cells, irrespective of P53 genotype
(Figure 5). Levels of IR-induced Chk1 S345 and S317 phosphor-
ylation (Chk1S345-P and Chk1S317-P) were stably high in wild
type cells but increased over time in p53-deficient cells. This effect
is likely due to the entry of G1/S checkpoint-defective P53
2/2
cells into S-phase (Figure 1C), when ATR activity is known to
increase [37]. RNAi-mediated knockdown of Cdk2 in a diverse
panel of human cell lines consistently reduced IR-dependent Chk1
phosphorylation (Figure S2A). In contrast, Chk2 phosphorylation
by ATM and the formation of DNA damage foci containing
phosphorylated ATM were unaffected by CDK2 genotype (Figure
S1C and S1D). These observations suggest that Cdk2 is required
for efficient ATR- but not ATM-mediated checkpoint signaling.
To determine how Cdk2 might control ATR signaling, we first
examined the status of ATR localization and known interacting
proteins. The ability of ATR to localize to DNA damage foci was
unaffected by disruption of CDK2 (Figure S2C), as was the
interaction between ATR and ATRIP, the requisite ATR binding
partner [38] (Figure S2D). ATRIP is phosphorylated on residue
S224 by Cdk2 [14] and this phosphorylation event has been
shown to contribute to G2/M checkpoint arrest. We observed that
cells lacking Cdk2 exhibited somewhat reduced ATRIP S224
phosphorylation (Figure S2B). Given the modest deficiency in
ATRIP phosphorylation, we investigated additional mediators that
might also contribute to checkpoint signaling by Cdk2.
One compelling candidate is the Cdk2 substrate Cdc6. Cdc6 is
a loading factor for the DNA replicative helicase complex required
for replication origin licensing [39]. In addition to its role in DNA
replication, Cdc6 has also been implicated as a regulator of
checkpoint function and mitotic entry [39–44]. In human cells,
depletion of Cdc6 causes cells with actively replicating DNA to
aberrantly enter mitosis [42], while overexpression of Cdc6 causes
Chk1 phosphorylation and G2/M arrest [40]. Cdc6 has also been
implicated in ATR-Chk1 signaling in fission yeast [41]and Xenopus
[44].
Inherently unstable, Cdc6 can be stabilized as a direct result of
phosphorylation by Cdk2 [45]. Although Cdc6 is an essential
DNA replication protein, cells lacking functional Cdk2 are able to
progress through S-phase despite significantly reduced Cdc6 levels
[6,45]. Therefore the relatively small amount of Cdc6 remaining
in Cdk2-deficient cells is clearly sufficient to support DNA
replication and cell cycle progression. In concordance with
previous studies, Cdc6 protein levels were decreased (Figure 5
and Figure S3A), and turnover was increased (Figure 6A), in
Cdk2-deficient cells. In checkpoint-deficient P53
2/2 cells, Cdc6
levels increased after IR in tandem with Chk1 phosphoprotein
(Figure 5). These results are consistent with a potential role for
Cdc6 in the regulation of the upstream kinase of Chk1, ATR.
In fission yeast, a direct interaction between the Cdc6 homologue
Cdc18 and the ATR homologue Rad3 is induced in response to
replication stress; this complex then activates checkpoint signaling
[41]. ATR and Cdc6 also interact following replication stress in
humancells[43].WeaskedwhetherCdc6andATRmightsimilarly
interact after IR. Complexes of endogenous ATR and Cdc6 were
detected after IR in HCT116 cells (Figure 6B). To confirm this
interaction we exogenously expressed HA-tagged Cdc6 (HA-Cdc6;
[45]) in HCT116 and CDK2-knockout cells and probed for an
interaction with ATR (Figure 6C). Exogenous expression of HA-
Cdc6 was higher in wild type cells (Figure 6C), which mirrored the
relative abundance of endogenous Cdc6 and further illustrated the
Figure 5. Impaired phosphorylation of Chk1 in Cdk2-deficient cells. Isogenic cells were treated with 12 Gy IR and harvested at the indicated
time points. Levels of the Chk1 phosphoproteins, Chk1S345-P and Chk1S317-P, Chk1 and Cdc6 were determined by immunoblot. Levels of a-tubulin
were assessed as a loading control.
doi:10.1371/journal.pgen.1000863.g005
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PLoS Genetics | www.plosgenetics.org 6 February 2010 | Volume 6 | Issue 2 | e1000863Figure 6. Stabilized Cdc6 facilitates Chk1 phosphorylation, associates with ATR, and controls mitotic entry. (A) Cdc6 protein stability
was analyzed by immunoblot in wild-type and CDK2
2/2 cells at the indicated times after cycloheximide treatment. Cdc6 levels were quantitated,
normalized to a-tubulin, and represented as a percentage relative to untreated control cells. (B) Physical interaction between endogenous Cdc6 and
ATR. Non-denatured cell lysates from the indicated cell lines were collected before or 4 h after 12 Gy IR. Lysates were subjected to
immunoprecipitation (IP) with anti–ATR or isotypic control (IgG) antibodies. Samples not subjected to immunoprecipitation were analyzed as whole
cell lysate. Levels of ATR and Cdc6 were determined by immunoblot. (C) Isogenic HCT116 cells were transfected with a plasmid expressing HA-tagged
Cdc6 (HA-Cdc6). Transfected cells were untreated or treated with 12 Gy IR and lysed after 4 h. Non-denatured cell lysates were subjected to
immunoprecipitation (IP) with anti–HA, anti–ATR, or isotypic control (IgG) antibodies. Samples not subjected to immunoprecipitation were analyzed
as whole cell lysate. Levels of ATR and HA-Cdc6 were determined by immunoblot. (D–F) U2OS cells were transfected with control (Con) or CDC6
(CDC6) siRNA. (D) Lysates were taken before and 4 h after treatment with 12 Gy IR. Chk1 and Cdc6 levels were analyzed by immunoblot. Relative
Chk1-phosphorylation (Chk1-P/Chk1) was determined by quantitation of Chk1S317-P plus Chk1S345-P followed by normalization to total Chk1. (E)
Cells were fixed and stained with Hoechst 33258 and subjected to flow cytometry before and 4 h after treatment with 12 Gy IR. (F) Cells fixed and
stained for histone H3S10-P before and 24 h after treatment with 4 Gy IR and 1 mg/ml nocodazole, mitotic index was determined by indirect
immunofluorescence. Error bars represent s.e.m. from three independent experiments. (G–I) CDK2
2/2 P53
2/2 cells were transfected with an empty
vector or Cdc6 expression vector. (G) Lysates were taken before and 4 h after treatment with 12 Gy IR. Chk1 and Cdc6 levels were analyzed by
immunoblot. (H) Cells were fixed and stained with Hoechst 33258 and subjected to flow cytometry before and 4 h after treatment with 12 Gy IR. (I)
Cells fixed and stained with Hoechst 33258 before and 24 h after treatment with 12 Gy IR and 0.2 mg/ml nocodazole, mitotic index was determined
by fluorescence microscopy. Error bars represent s.e.m. from six independent experiments.
doi:10.1371/journal.pgen.1000863.g006
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precipitated with HA-Cdc6, and the amount of ATR bound
increased after IR treatment (Figure 6C, Figure S3C and S3D). In
the reciprocal experiment, ATR was able to pull down increased
HA-Cdc6 after IR treatment in both HCT116 and U2OS cell lines
(Figure 6C and Figure S3B). The coimmunoprecipitation of Cdc6
and ATR was not disrupted by 50 mg/ml ethidium bromide,
suggesting that this interaction is specific and not simply mediated
by DNA (data not shown).
We could not reliably detect ATR-Cdc6 complexes in CDK2
2/2
cells, before or after IR (Figure 6B and 6C). As Cdc6 stability and
protein levels were markedly decreased in CDK2-knockout cells
(Figure 6A–6C and Figure S3A), we asked whether the lack of
detectable interaction was simply due to reduced Cdc6 protein
levels or, alternatively, if loss of Cdk2-dependent phosphorylation
on Cdc6 directly disrupted its interaction with ATR. Mutant Cdc6
proteins, wherein the Cdk2-phosphorylated serine residues (S54,
S74, S106) were replaced either with non-phosphorylatable
alanine residues (HA-Cdc6AAA) or with phosphomimetic aspartic
acid residues (HA-Cdc6DDD; [45]), were expressed and pulled
down. ATR co-precipitated with HA-Cdc6AAA in wild type
HCT116 cells and with HA-Cdc6DDD in CDK2
2/2 cells (Figure
S3C and S3D). These results indicate that the ATR-Cdc6
interaction is independent of Cdc6 phosphorylation by Cdk2 per
se, and that the differences in complex formation observed were
most likely the result of decreased Cdc6 levels caused by Cdk2
deficiency.
To examine whether Cdk2-mediated stabilization of Cdc6
could functionally contribute to ATR-Chk1 signaling, we
experimentally manipulated Cdc6 levels. First, we knocked down
Cdc6 by siRNA. Cdc6 protein levels could be transiently lowered
in U2OS cells, which express wild type p53, by siRNA transfection
(Figure 6D).
The effects of Cdc6 levels on cell growth have been intensively
studied. Depending on the extent and timing of Cdc6 depletion
and the type of target cell, Cdc6 knockdown has been shown to
result in variable changes to cell cycle distribution as well as cell
death [42,46–51]. In many cases, transient depletion of Cdc6 in
various cell types, including HCT116 [46,48,51], has been
reported to have minimal effects. Normal cells and cancer cells
have been observed to respond differently to Cdc6 knockdown
[49,52], but the genetic alterations in cancer cells that might
underlie such differences have not been conclusively identified. We
observed that changes to the cell cycle distribution 48 h after
partial Cdc6 knockdown were minimal, with a similar proportion
of cells in S-phase and a small decrease of cells in G1 (Figure 6E).
Knockdown of Cdc6 caused a reduction in IR-induced Chk1
phosphorylation (Figure 6D) that was reminiscent of the observed
changes in checkpoint signaling after CDK2 knockdown (Figure
S2A) or knockout (Figure 5). While knockdown of Cdc6 was less
efficient in HCT116 cells, decreased Cdc6 also led to reduced IR-
induced Chk1 phosphorylation, irrespective of P53 genotype
(Figure S3E). Knockdown of Cdc6 also led to increased levels of
the Chk1 target Cdc25A, before and after IR treatment (Figure
S3F and S3G). To determine if Cdc6 protein levels could
functionally impact G2/M checkpoint arrest, we assessed mitotic
index after CDC6 knockdown followed by sequential treatment
with IR and nocodazole. Twenty-four hours after IR/nocodazole
treatment, cells pretreated with CDC6 siRNA entered mitosis in
higher numbers as compared with control siRNA (Figure 6F).
We next increased Cdc6 levels by transient transfection of an
untagged Cdc6 expression construct. While partial restoration of
Cdc6 expression in CDK2
2/2 P53
2/2 knockout cells did not
appreciably alter the cell cycle profile (Figure 6H), it did result in
increased IR-induced Chk1 phosphorylation (Figure 6G) and
reduced mitotic entry after IR/nocodazole treatment (Figure 6I).
Together, the results of these overexpression and knockdown
experiments suggest that stabilization of Cdc6 by Cdk2 contributes
to efficient IR-induced Chk1 phosphorylation by ATR and p53-
independent G2/M checkpoint function. The Cdk2-Cdc6 path-
way appears to have a direct affect on ATR-Chk1 signaling, as cell
cycle profiles were only minimally changed by Cdc6 manipulation
under these conditions (Figure 6E and 6H).
Discussion
Studies of knockout mice have now unequivocally shown that the
essential S-phase functionspreviously attributed toCdk2 canalsobe
conducted by Cdk1 in somatic cells [3–5]. These seminal
observations raised the question of why mammalian cells express
multiple Cdks that appear to be non-essential. In this report, we
demonstrate that loss of Cdk2 alters the regulation of several
proteins that are known to regulate S-phase progression, but also
control mitotic entry, including Cdc25A, Chk1, Cdc6 and ATRIP
[33,39,53]. The altered balance of these bifunctional proteins did
not affect the transition of CDK2
2/2 cells through the phases of the
unperturbed cell cycle, but did compromise their ability to mount
effective checkpoint signaling through the ATR-Chk1 pathway.
Cdk2 and Cdk1 are therefore redundant with respect to essential
cell cycle functions, but have distinct, non-redundant roles in a key
DNA damage response. IR-induced ATR activation is restricted to
the S- and G2-phases [37], when Cdk2 is normally active. We show
that Cdk2 plays a unique role in facilitating robust DNA damage
checkpoint control by the ATR-Chk1-Cdc25A pathway. Cdk2
appears to promote the formation of active ATR complexes in at
least two ways: via the phosphorylation of ATRIP and by the
stabilization of Cdc6 (Figure 7). It is possible that Cdk2 also controls
checkpoint signaling through additional mechanisms such as the
recently described Cdk2 interacting protein (CINP) which facilitates
robust ATR signaling [54].
At present the precise mechanism by which Cdc6 affects ATR
signaling remains unclear. Our data suggest that Cdk2-mediated
phosphorylation of Cdc6 merely regulates Cdc6 levels but is not
otherwise required for ATR-Cdc6 complex formation (Figure
S3C). In agreement with our results, a paper published during the
Figure 7. The proposed role of Cdk2 in the p53-independent
regulation of Cdk1. Cdk2 directly phosphorylates at least two
proteins, ATRIP and Cdc6, that directly regulate the G2-M transition via
the ATR-Chk1-Cdc25A pathway. The activity of Cdk1 is independently
inhibited upon activation of the p53-p21 pathway, which is defective in
many cancer cells. See text for additional details.
doi:10.1371/journal.pgen.1000863.g007
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between ATR and Cdc6 in human and Xenopus cells [51] and
showed that the non-phosphorylatable Cdc6-AAA mutant could
interact with ATR, albeit with somewhat lower efficiency. The
fission yeast Cdc6 homologue Cdc18 is required to anchor the
ATR homologue Rad3 to chromatin [41], but our results suggest
that Cdc6 may not perform an analogous function in human cells
(Figure S2B). Further study is required to determine if Cdc6 might
directly affect ATR catalytic activity, or if Cdc6 might promote the
assembly of higher order complexes required for full ATR
activation.
In conjunction with checkpoint pathways that target Cdk1 via
Cdc25 phosphatases, the exclusion of Cdk1 from the nucleus is an
important G2/M checkpoint mechanism [23]. In mouse [15] and
human (Figure 3B and 3C) cells lacking Cdk2, Cdk1 becomes
aberrantly localized to the nucleus. It would therefore appear that
the formation of non-canonical Cdk1-cyclin heterodimers that
allow Cdk1 to compensate for Cdk2 in the completion of S phase
in unperturbed cells [11,24,25] also impairs the ability of damaged
cells to arrest at G2/M. We propose that the temporal division of
respective S-phase and G2-phase functions between Cdk2 and
Cdk1 is a critical feature of the metazoan cell cycle that allows its
progress to be efficiently halted after DNA damage.
Defective checkpoints are a feature of the majority of human
cancers [55–57]. In many cancers, checkpoint deficiencies are
caused by loss-of-function mutations in P53. The genetic
interaction between P53 and CDK2 described here demonstrates
a novel, non-redundant requirement for Cdk2 in the p53-




Endogenous CDK2 and P53 loci were disrupted in HCT116
cells using recombinant adeno-associated virus (rAAV)-based gene
targeting methods [58,59]. Briefly, the targeting constructs pAAV-
CDK2 and pSEPT-p53 [58] were packaged into infectious rAAV
subsequently used to generate transgenic clones. Identification and
expansion of homologous recombinant cell lines was performed as
described [59]. At least two independent clones were isolated and
analyzed for each cell line.
Cell culture, siRNA, and cell cycle analysis
HCT116, SW480 and derivatives were cultured in McCoys 5A
supplemented with 6% FCS. U2OS cells were cultured in DMEM
supplemented with 10% FCS. CDK2 and CDC6 siRNA pools and
non-targeting control pools were purchased from Dharmacon.
Transfections were performed with 100 nM siRNA and Lipofec-
tamine 2000 (Invitrogen). In HCT116, optimal Cdk2 knockdown
was achieved by two transfections 48 h apart and cells were
analyzed 96 h after initial transfection. In SW480, optimal Cdk2
knockdown was achieved by a single transfection and cells were
analyzed after 72 h. Cdc6 knockdown was achieved by a single
transfection and cells were analyzed after 48 h. IR and nocodazole
treatment were performed as described [17]. For cell cycle analysis
cells were fixed, stained with Hoechst 33258 and analyzed by flow
cytometry or microscopy for mitotic chromosome condensation as
described [17]. Mitotic index for U2OS cells were determined by
immunofluorescence for histone H3S10-P staining.
Protein analysis
Total cell lysates were prepared using NuPAGE sample buffer
(Invitrogen). Non-denatured cell lysates for immunoprecipitation
were collected in Cell Lysis Buffer (Cell Signaling). Immunopre-
cipitations were performed by incubation of lysates with antibody
and Protein A/G PLUS-Agarose beads (Santa Cruz) overnight at
4uC. Beads were washed, resuspended and boiled in NuPAGE
lysis buffer. Proteins were separated on NuPAGE gels (Invitrogen),
transferred to PVDF membranes, probed with antibodies and
developed using Enhanced Chemiluminescence (Amersham).
Primary antibodies were directed against a-tubulin, ATR, Cdc6,
Cdk1, Cdk2, Chk1, cyclin A, cyclin E, cyclin B1, HA, p53 (Santa
Cruz), Cdc25A (Neomarkers), ATMS1981-P, Cdk1Y15-P,
Chk1S317-P, Chk1S345-P, Chk2T68-P (Cell Signaling), ATRIP,
histone H3S10-P (Millipore), Orc2 (BD Biosciences), and AT-
RIPS224-P (a gift from D Cortez), as indicated. The Quantity One
4.6.1 software package (Bio-Rad) was used for quantitation. For
analysis of protein stability, cells were incubated in 100 mg/ml
cycloheximide prior to lysis; band intensities were measured and
normalized to a-tubulin abundance. Protein levels were expressed
as a percentage of untreated control cells.
Cell fractionation and immunofluorescence microscopy
Subcellular fractionation was performed as described [60]. For
immunofluorescence, cells were grown on chamber slides and
fixed with 3.75% paraformaldehyde/2% sucrose. Fixed cells were
permeabilized in 0.2–0.5% Triton X-100 and blocked in BSA.
Immunofluorescence staining was performed using Cdk1, cyclin
A, cyclin B1, cyclin E or histone H3S10-P antibodies followed by
biotin-conjugated secondary antibody (Santa Cruz) and Alexa-488
conjugated avidin (Molecular Probes). Cells were counterstained
with 49-69-diamidino-2-phenylindole (DAPI) and mounted with
Fluoromount-G (Southern Biotech). Images were captured at
room temperature using an AxioImager Z1 microscope equipped
with an AxioCam HRm camera, Axiovision 4.6.3 software, and a
Plan Neofluar 20x/0.25NA, 40x/1.3NA or 63x/1.25NA lens
(Zeiss), as indicated. Images were processed for brightness and
contrast using Adobe Photoshop.
Retroviral gene transfer
CDC25A shRNA was cloned from pSUPER-Cdc25A [61] into
the retroviral plasmid pBabe to generate pBabe-shCDC25A.
Retroviral production using Amphopack293 cells (Clontech) and
subsequent gene transfer was performed according to protocols
supplied by the manufacturer.
Plasmids
Plasmids encoding HA-Cdc6, HA-Cdc6AAA and HA-
Cdc6DDD were previously described [45]. To generate the
untagged full length Cdc6 construct, human Cdc6 cDNA was
cloned into pCDNA3.1/Hygro (Invitrogen). Cells were transfected
using Lipofectamine 2000 (Invitrogen) and analyzed after 24–
48 h.
Supporting Information
Figure S1 Checkpoint signaling in HCT116 cells and isogenic
derivatives in response to ionizing radiation. (A) Isogenic HCT116
cells were treated with 5 Gy, 8 Gy, or 12 Gy IR followed by
0.2 mg/ml nocodazole. Cells were fixed and stained with Hoechst
33258. Mitotic index was assessed by counting condensed
chromosomes. Error bars represent s.e.m. from three independent
experiments. (B) CDK2
2/2 P53
2/2 clones stably expressing
Cdc25A shRNA from Figure 4E were treated with 0.2 mg/ml
nocodazole. Mitotic index was assessed at the indicated times.
Error bars represent s.e.m. from six clones. (C) Isogenic cells were
harvested after treatment with 12 Gy IR. Levels of Chk2T68-P,
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(D) HCT116 and CDK2
2/2 cells were fixed with 3.75%
paraformaldehyde and permeabilized with 0.5% Triton-X-100.
Fixed cells were stained using anti-ATMS1981-P antibody and
counterstained with DAPI. Cells were fixed before and 3 h after
treatment with 10 Gy IR. Images were captured at 636
magnification (scale bar, 10 mm).
Found at: doi:10.1371/journal.pgen.1000863.s001 (1.01 MB TIF)
Figure S2 Effects of Cdk2 deficiency on the ATR-Chk1 pathway.
(A) Levels of the indicated proteins were determined by immunoblot
in human U2OS osteosarcoma cells, MCF7 breast adenocarcinoma
cells, H1299 lung adenocarcinoma cells, and SW480 colorectal
adenocarcinoma cells before and after treatment with 12 Gy IR.
U2OS and MCF7 lysates were collected 0.5 h after IR. H1299 and
SW480 lysates were collected 2 h after IR. Cells transfected with
siRNA directed against CDK2 (CDK2) were compared with cells
transfected with control siRNAs (Con). (B) Levels of ATRIPS224-P in
untreated isogenic HCT116 cells were determined by immunoblot,
quantitated and normalized to a-tubulin. (C) HCT116 and CDK2
2/2
cells were simultaneously fixed and permeabilized with 4% parafor-
maldehyde and 0.5% Triton-X-100. Fixed cells were stained using
anti–ATR antibody and counterstained with DAPI. Cells were fixed
before and 20 h after treatment with 12 Gy IR. Images were captured
at 636magnification (scale bar, 10 mm). (D) Non-denatured cell lysates
from the indicated cell lines were collected before or 4 h after 12 Gy
IR. Lysates were subjected to immunoprecipitation (IP) with anti-ATR
or control (IgG) antibodies. Samples not subjected to immunoprecip-
itation were analyzed as whole cell lysate. Levels of ATR and ATRIP
were determined by immunoblot.
Found at: doi:10.1371/journal.pgen.1000863.s002 (0.58 MB TIF)
Figure S3 Interaction of Cdc6 with ATR and modulation of
Chk1-Cdc25A signaling. (A) Levels of Cdc6 were determined by
immunoblot in the indicated isogenic cell lines. (B–D) Non-
denatured cell lysates were collected before or 4 h after treatment
with 12 Gy IR. Lysates were subjected to immunoprecipitation
(IP) with anti–ATR, anti–HA, or IgG isotype control antibodies.
Lysates not subjected to immunoprecipitation were analyzed as
Whole Cell Lysate. Levels of ATR and HA-Cdc6 in were
determined by immunoblot. Lysates for immunoprecipitation were
collected from (B) U2OS cells transfected with a plasmid
expressing HA-Cdc6, (C) HCT116 transfected with a plasmid
expressing HA-Cdc6 or HA-tagged non-phosphorylatable Cdc6
(HA-Cdc6-AAA), and (D) HCT116 and CDK2
2/2 transfected
with a plasmid expressing HA-Cdc6 or HA-tagged phosphomi-
metic Cdc6 (HA-Cdc6-DDD). (E) Chk1 levels were determined by
immunoblot in isogenic HCT116 cells transfected with control
(Con) or CDC6 (CDC6) siRNA. Lysates were taken before and
4 h after treatment with 12 Gy IR. (F) Cdc25A levels were
determined by immunoblot in U2OS or isogenic HCT116 cells
transfected with control or CDC6 siRNA. (G) Cdc25A levels were
determined by immunoblot in U2OS cells transfected with control
or CDC6 siRNA before and 4 h after treatment with 12 Gy IR.
Found at: doi:10.1371/journal.pgen.1000863.s003 (0.47 MB TIF)
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